Literature DB >> 19194655

Fronto-mesial WHO grade II and III gliomas: specific aspects of tumours arising from the anterior cingulate gyrus.

Hans-Jakob Steiger1, Mathias Göppert, Frank Floeth, Bernd Turowski, Michael Sabel.   

Abstract

A total 17 fronto-mesial grade II and III gliomas among a total of 64 frontal grade II and III gliomas underwent surgical resection between January 2003 and June 2007. Eleven fronto-mesial gliomas originated from the anterior cingulate gyrus, while the others originated from the genu of the corpus callosum. None of the grade II or III gliomas originated from the gyrus rectus. Anterior cingulate gliomas exhibited distinct features with regard to presenting symptoms, MRI, histopathology and prognosis. Epilepsy was the dominant presenting symptom of anterior cingulate tumours. Five of the 11 gliomas had a sharp border on MRI. Four of the 11 were histopathologically classified as WHO grade II and seven as WHO grade III and an oligodendrocytic component was apparent in eight of the 11 specimens. Comparison of the post-operative survival with the entire set of frontal gliomas showed a trend that anterior cingulate tumours had a more favourable prognosis.

Entities:  

Mesh:

Year:  2009        PMID: 19194655     DOI: 10.1007/s00701-008-0160-x

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  2 in total

1.  Resection of gliomas in the cingulate gyrus: functional outcome and survival.

Authors:  Ági Oszvald; Johanna Quick; Kea Franz; Erdem Güresir; Andrea Szelényi; Hartmut Vatter; Volker Seifert
Journal:  J Neurooncol       Date:  2012-06-02       Impact factor: 4.130

Review 2.  Gliomas Infiltrating the Corpus Callosum: A Systematic Review of the Literature.

Authors:  Paolo Palmisciano; Gianluca Ferini; Gina Watanabe; Christian Ogasawara; Emal Lesha; Othman Bin-Alamer; Giuseppe E Umana; Kenny Yu; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Ali S Haider
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.